Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced today at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion euros in its new R&D programme over the next five years. Of the total investment, 5 billion euros will go to preclinical R&D with 1.5 billion euro thereof planned for collaborations with external partners. The company is aiming to develop the next generation of medical breakthroughs and maintain its excellent competitive position. The new R&D strategy embraces open innovation in the form of external collaborations to better leverage emerging science and Boehringer Ingelheim’s experience and capabilities for the discovery of new medicines.
“With eleven new launches in 2014 and 2015, our R&D organisation is an example of Boehringer Ingelheim’s outstanding capability in this field,” said Professor Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim. “The new programme and strategy reflect our corporate philosophy of long-term, sustainable growth. They will enable us to continue our excellent track record of bringing therapeutic innovations with high value for patients to the market.”
A New R&D Strategy
A key element of the new strategy is an increased focus on collaborations with external partners, while maintaining strong internal R&D capabilities. This approach will enable the company to build on its long-term experience and strength in its core therapeutic areas while expanding its efforts to access the vast creative pool of global biomedical research through open innovation.
“Our new strategy embraces the trend towards more extensive open-innovation approaches between academia and industry in biomedical research. Our partners benefit by accessing our broad experience and capabilities and through establishment of long-term personal interactions with our R&D teams,” explained Dr Michel Pairet, senior corporate vice president research and non-clinical development at Boehringer Ingelheim and designated Member of the Board of Managing Directors from January 2016 onwards. “The new strategy will foster our external collaboration efforts by enabling us to be faster and more flexible. This is of essence for research beyond the borders of our current focus areas, where we explore emerging science, new indications and new technology to expand opportunities.”
Cooperation with Partners along the entire R&D value chain
Open innovation has become a fundamental part of drug discovery. The R&D organisation of Boehringer Ingelheim is working with the wider scientific world to embed a range of innovative opportunities in its R&D endeavours.
Firstly, bilateral collaboration agreements with academic investigators and biotechnology companies provide important starting points for drug discovery projects. Boehringer Ingelheim has entered into several new research collaborations in exciting areas of science with partners that are worldwide leaders in their fields.
Boehringer Ingelheim just announced new collaborations with four major scientific partners to enrich R&D with novel therapeutic approaches for patients suffering from inflammatory bowel disease (IBD), namely the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine. These four collaborations aim to identify and validate potential new therapeutic targets as well as identify biomarkers that offer the potential to address the significant unmet medical needs of patients suffering from IBD such as Crohn’s disease and ulcerative colitis. Boehringer Ingelheim has also recently signed exclusive agreements with Hanmi Pharmaceuticals in Korea to develop a third generation EGFR-targeted therapy for lung cancer and with Circuit Therapeutics, California to apply the technique of optogenetics to find new treatments for psychiatric disorders and cardiometabolic diseases.
Secondly, public-private partnerships, such as the Structural Genomics Consortium (SGC), Innovative Medicines Initiative (IMI) and the G-protein coupled receptor (GPCR) Consortium, are playing an increasingly important role in medicines discovery because of their ability to bring together the best academic and industrial scientists in an unrestricted precompetitive field. Boehringer Ingelheim is an active participant in all two of these successful public-private partnerships and recently joined the GPCR Consortium.
Thirdly, crowdsourcing initiatives with organisations such as InnoCentive and the BioMed X Innovation Center can be used to seek scientists with bright ideas to address important medical challenges. Boehringer Ingelheim and the BioMed X Innovation Center recently announced that they are bringing together outstanding scientists at an academic centre of excellence in Heidelberg and providing them with appropriate infrastructure and mentorship to work on new epigenetic approaches to chronic obstructive pulmonary disease.
In addition, Boehringer Ingelheim invests in the Institute for Molecular Pathology (IMP) in Vienna to support basic research, and a global network of scientists as essential elements of the creative endeavour. Finally, the Boehringer Ingelheim Venture Fund, founded in 2010 with an initial financial commitment of 100 million euro, is currently investing in a portfolio of 13 different start-up companies with exciting new therapeutic ideas.
The new R&D strategy is an important building block of Boehringer Ingelheim’s global strategy to be prepared for chances and challenges in the pharmaceutical market. “This is another decisive step to position Boehringer Ingelheim for long-term growth,” said Professor Barner. “We are looking forward to addressing unresolved challenges in immunology, respiratory and cardiometabolic medicine, as well as in oncology, in diseases of the central nervous system and beyond.”
Source: Boehringer Ingelheim
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”